AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2014
May 27, 2014
31868_dirs_2014-05-27_80b836e9-2e23-458e-8069-e9f3ac51da63.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2014-05-22
Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-05-22 | Common Stock | M | 17685 | $3.78 | Acquired | 144301 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-05-22 | Stock Option (Right to Buy) | $3.78 | M | 17685 | Disposed | 2021-07-01 | Common Stock (17685) | Direct |
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20